開拓藥業-B(09939.HK):普克魯胺臨牀試驗於第14天達到主要終點
格隆匯3月11日丨開拓藥業-B(09939.HK)發佈普克魯胺治療COVID-19重症患者的臨牀試驗結果。於臨牀試驗中,普克魯胺於第14天達到主要終點,表明世界衞生組織COVID-19等級量表下由5.663的基線下降4.01至1.653,而對照組則由5.618的基線下降0.25至5.368(p值低於0.0001)。普克魯胺同樣表明了可降低92%患者死亡風險(3.7%對比47.6%)並縮短住院時間中位數9天(住院時間中位數5天對比14天)。
臨牀試驗屬普克魯胺治療COVID-19重症患者的多中心、隨機、雙盲、安慰劑平行對照的研究。臨牀試驗將設置男性及女性兩個隊列,每個隊列分為普克魯胺組及對照組兩個組別。其最初招募了588名符合所有資格標準的患者,該等患者在入院後48小時內獲招募。
在普克魯胺組中,患者將每日口服一次(QD)300毫克普克魯胺,持續14天。在對照組中,患者將每日口服一次(QD)普克魯胺安慰劑,持續14日。各隊列亦將接受臨牀醫生推薦的標準治療藥物。臨牀試驗的主要終點是在第14日通過世界衞生組織COVID-19等級量表評估的普克魯胺組相對於對照組的有效性。
於2021年3月9日進行的初步分析乃基於普克魯胺組的294名患者(其中56.8%為男性)及對照組的296名患者(其中57.8%為男性)。根據於第14日的結果,普克魯胺組的死亡人數為11人(3.7%),而對照組的死亡人數為141(47.6%),表明死亡風險下降92%。普克魯胺組使用新機械通氣(MV)及╱或死亡人數為13人(4.4%),而對照組為156人(52.7%),表明死亡風險下降92%。普克魯胺組的住院時間中位數為5天,而對照組為14天,表明普克魯胺縮短9日住院時間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.